The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.

The researchers found that 45,693 outpatient visits, 15,866 emergency department visits, and 7571 hospitalizations among infants would be prevented each year by year-round maternal vaccination.

In most parts of the U.S., the RSV season lasts from October through March and peaks in December or January. Nirsevimab immunization is for infants under 8 months of age during RSV season.